An international multicentre trial involving UK researchers has demonstrated that a new personalised cancer treatment can radically improve the outlook for some patients with bile duct cancer. In ...

The liver creates a digestive juice called bile and stores it in the gall bladder. While eating, the gall bladder forces the bile through a gall bladder tube called the bile duct. Bile duct cancer, or ...

Salvatore Papa receives funding from AAMF-The Cholangiocarcinoma Charity, Guts UK, Rosetrees Trust and Blood Cancer UK. Concetta Bubici receives funding from Guts UK, Rosetrees Trust and Blood Cancer ...

Bile duct cancer, or cholangiocarcinoma, is a serious concern due to its rapid progression and often mild, easily mistaken ...

Cancer is a disease that can be treated more effectively if diagnosed early. However, some types of cancer have mild early ...

Cholangiocarcinoma better known as bile duct cancer; is a rare but aggressive form of cancer occurring commonly in individuals over the age of 50. The tumors of bile duct are difficult to treat and ...

The bile ducts are a series of tubes that reach from the liver to the small intestine. The bile ducts move bile from the liver and the gallbladder to the small intestine where it helps digest the fats ...

Highly-Specific Allosteric ACLY Inhibitor Designed to Target Liver and Bile Duct Injury, Inflammation, and Fibrosis Associated with Primary ...

(RTTNews) - The U.S. Food and Drug Administration (FDA) granted accelerated approval to Incyte Corp.'s Pemazyre (pemigatinib) as the first treatment approved for adults with certain types of ...

Inflammation and scarring of the bile ducts—also known as cholangiopathies—can stop the bile from flowing, a vital fluid that helps digest fats. When bile can’t move through these ducts, it backs up ...

Bile duct cancer, or cholangiocarcinoma, is a rare type of cancer that starts in the bile ducts. Bile ducts are small tubes in your body that carry bile (digestive fluids) from your liver and ...

Biliary atresia is a devastating pediatric liver disease, and for clinicians, the challenge isn't just treatment, but also beating a relentless clock.